candriam investors group  leading paneuropean multispecialist asset manager  asset management and investment solutions  candriamcom by continuing to browse this site you are agreeing to cookies being used to offer content and services adapted to your interests find out more about cookies on candriamcom accept and continue on this site rest of the world austria belgium canada chili denmark finland france germany hong kong ireland italy japan luxembourg netherlands norway portugal singapore slovakia south korea spain sweden switzerland united kingdom united states of america en professional investor i am a private investor login candriamabout usmarket insightsfunds  solutionspress roomwork at candriam my subscriptions my wishlist contact search for a fund my subscriptions contact topics absolute returnasset allocationsrifixed incomemacroequities highlighted monthly strategic insightfrench electionsbrexitukall qasopinionsvideoresearch papers authors jan boudewijnsanton brenderisabelle cabienadège dufossénicolas forestphilippe noyardfabien orèvegeoffroy goenenflorence pisanikoen popleukoen van de maelerudi van den eyndewim van hyftepatrick zeenni resources publicationssri publicationsall qasresearch papersvideo article  rest of the world austria belgium canada chili denmark finland france germany hong kong ireland italy japan luxembourg netherlands norway portugal singapore slovakia south korea spain sweden switzerland united kingdom united states of america en professional investor i am a private investor login my subscriptions contact about usmarket insightsfunds  solutionspress roomwork at candriam search for a fund topics absolute returnasset allocationsrifixed incomemacroequities highlighted monthly strategic insightfrench electionsbrexitukall qasopinionsvideoresearch papers authors jan boudewijnsanton brenderisabelle cabienadège dufossénicolas forestphilippe noyardfabien orèvegeoffroy goenenflorence pisanikoen popleukoen van de maelerudi van den eyndewim van hyftepatrick zeenni resources publicationssri publicationsall qasresearch papersvideo article  july   china  is the bond connect a real opportunity  the launch of the stock connect platform in  was the single biggest step towards opening onshore capital markets to foreign investors  read more july   be steady – change could come relatively soon as widely expected the fomc kept the target range for the federal funds rate unchanged at  no press conference  read more july   cart therapy one step closer to patients last week a panel of oncology experts summoned by the fda voted unanimously in favour of novartis’ groundbreaking cart cancer therapy  read more asset allocation july   last week investors closely monitored the ecb meeting on thursday read more macro july   in the us the philadelphia fed manufacturing index fell to  from  in june reporting solid but slowing growth in july read more equities july   slightly negative week for european equities read more fixed income july   global sovereign yields dropped as the ecb reiterated that inflation levels were not yet to the anticipated figures read more market july   markets figures read more discover candriams houseview for this week subscribe to our weekly newsletter robotics  no longer scifi april   navigate all market conditions may   sri bestinclass march   see all videos july   super mario thinks about giving his super powers back this is the story of an american an italian and an english central banker who meet in sintra what do they talk about they managed to surprise the markets by maintaining a rates normalization rhetoric despite inflation figures below target read more july   the upcoming expansion is the second step of global reflation after the recovery in  as expected central banks are now at the forefront the key question for the coming months is the resilience of equity markets to this tightening bias read more july   europe consolidates after a solid first quarter in our view the eurozone is still the most attractive market read more july   long sek  nok jpy remains a safehaven we note that the overall framework for the euro has turned negative vs certain currencies sek and yen based primarily on tactical factors and is less positive vs the us dollar than before read more july   spread trade long us vs short eurozone partial profittaking activity cycle momentum continues to strengthen in the eurozone and in japan as the expansion stage remains wellanchored in both regions read more july   neutral exposure to expensive credit markets maintained the slowing debt cycle tighter credit spreads and lesser central bank support entice us to take a rather cautious and neutral view on the corporate bond universe read more july   overweight high yielders and energy complex underweight treasury sensitive credits external risks to em have declined consistently since the beginning of the year as dm political uncertainty subsided with european elections  read more july   big data mining value for the asset management industry a byproduct of the internet big data technology is now being applied within numerous economic sectors including the asset management industry read more july   looking for stability given our confidence in the sustainability of positive global growth and more hawkish central banks throughout the next quarters candriam remains strategically overweight equities and keeps an underweight and short duration on fixedincome for h  read more our experts anton brender chief economist read all his articles florence pisani global head of economic research read all her articles geoffroy goenen head of fundamental europe equity management read all his articles isabelle cabie global head of responsible development read all her articles jan boudewijns head of emerging equity management read all his articles koen popleu deputy head of fundamental equity management read all his articles koen van de maele global head of investment engineering read all his articles nadège dufossé head of asset allocation read all her articles nicolas forest global head of fixed income management read all his articles patrick zeenni deputy head of high yield  credit arbitrage management read all his articles philippe noyard head of high yield  credit arbitrage management read all his articles rudi van den eynde head of thematic global equity read all his articles see all experts looking for a fund look it up here search for a fund contact us we value your input and welcome your questions and comments contact candriam “conviction and responsibility in asset management” one of europe’s leading asset managers  experienced professionals multispecialist in traditional alternative and sri management  years of experience part of new york life a fortune company  bn€ assets under management on march  convictiondriven investment solutions in  areas absolute return asset allocation equity fixed income sustainable  responsible investments presence in several european countries and in selected highpotential region amsterdam brussels dubai frankfurt geneva new york city london luxembourg madrid milan paris latest newsabout candriam  dec montreal carbon pledge – candriam discloses its carbon footprint  oct candriam embed principles of the uk stewardship code  sep candriam the right partner for sustainable development follow us on social media   contact candriam contact us candriam “conviction and responsibility in asset management” follow us on social media   contact candriam contact us  candriam all rights reserved  legal information  regulatory information  contact us × my country of residence austria belgium canada chili denmark finland france germany hong kong ireland italy japan luxembourg netherlands norway portugal rest of the world singapore slovakia south korea spain sweden switzerland united kingdom united states of america i confirm i am a nonqualified investor regulated  unregulated qualified investor professional investor private investor and agree with and will comply to the terms and conditions below by clicking on i agree you acknowledge having your usual residence in the country you will select if not then you acknowledge and accept that you must click on the button i disagree in order to return to the home page of this site where you can then make the right choice in fact the information available on this site is only intended for physical persons with their usual residence in the country concerned or for companies with their registered office in the country selected candriam therefore has no liability whatsoever for any harm of loss of opportunity resulting from the fact that you were given access to this site after selecting a country other than your own the information given on this site constitutes neither an offer nor an invitation to negotiate purchase andor sell the financial instruments mentioned by clicking on the i agree button below you acknowledge and accept that the use of and access to the information andor services accessible via this site is subject to acceptance of the provisions referred to in the legal information which on the example of this important information constitute the conditions imposed by candriam for the use of its site candriam reserves the right unilaterally and at any time to amend this important information as well as the legal information your use of the site is subject to the most recent version both of the important information and the legal information by clicking on i agree you acknowledge having your usual residence in the country you will select if not then you acknowledge and accept that you must click on the button i disagree in order to return to the home page of this site where you can then make the right choice in fact the information available on this site is only intended for physical persons with their usual residence in the country concerned or for companies with their registered office in the country selected candriam therefore has no liability whatsoever for any harm of loss of opportunity resulting from the fact that you were given access to this site after selecting a country other than your own the information given on this site constitutes neither an offer nor an invitation to negotiate purchase andor sell the financial instruments mentioned by clicking on the i agree button below you acknowledge and accept that the use of and access to the information andor services accessible via this site is subject to acceptance of the provisions referred to in the legal information which on the example of this important information constitute the conditions imposed by candriam for the use of its site candriam reserves the right unilaterally and at any time to amend this important information as well as the legal information your use of the site is subject to the most recent version both of the important information and the legal information decline confirm  agree × username password forgot your password  decline confirm  agree or become a member × disconnect manage account candriam investors group  leading paneuropean multispecialist asset manager  asset management and investment solutions  candriamcom by continuing to browse this site you are agreeing to cookies being used to offer content and services adapted to your interests find out more about cookies on candriamcom accept and continue on this site rest of the world austria belgium canada chili denmark finland france germany hong kong ireland italy japan luxembourg netherlands norway portugal singapore slovakia south korea spain sweden switzerland united kingdom united states of america en professional investor i am a private investor login candriamabout usmarket insightsfunds  solutionspress roomwork at candriam my subscriptions my wishlist contact search for a fund my subscriptions contact corporate profile our vision ceo speaking corporate news candriam the right partner for sustainable developmentpaper consumption at candriamparis ecotrail a good first experience for candriamcandriam embed principles of the uk stewardship codecandriam celebrates  years of sri and publishes survey resultsmedia coverage of candriam’s  results our responsibilities responsible in our investmentsmeeting clientsneedsmotivated empowered teamsresponsibility towards the environment and society esg news rest of the world austria belgium canada chili denmark finland france germany hong kong ireland italy japan luxembourg netherlands norway portugal singapore slovakia south korea spain sweden switzerland united kingdom united states of america en professional investor i am a private investor login my subscriptions contact about usmarket insightsfunds  solutionspress roomwork at candriam search for a fund corporate profile our vision ceo speaking corporate news candriam the right partner for sustainable developmentpaper consumption at candriamparis ecotrail a good first experience for candriamcandriam embed principles of the uk stewardship codecandriam celebrates  years of sri and publishes survey resultsmedia coverage of candriam’s  results our responsibilities responsible in our investmentsmeeting clientsneedsmotivated empowered teamsresponsibility towards the environment and society esg news candriam about us candriam investors group a sustainable and responsible financial player naïm aboujaoudé ceo of candriam and chairman of new york life investment management international learn more   corporate profile our vision learn more conviction  responsibilityin asset management learn more our responsibilities responsible in our investments learn more latest news candriam embed principles of the uk stewardship code october   candriam the right partner for sustainable development september   paper consumption at candriam august   sri bestinclass august   meeting the needs of our clients learn more motivated empowered teams learn more responsibility towards the environment and society learn more library in the spotlight snapshot of candriam investors group download file all publications  pressroom discover our latest press releases download the press kit learn more contact us we value your input and welcome your questions and comments contact candriam “conviction and responsibility in asset management” one of europe’s leading asset managers  experienced professionals multispecialist in traditional alternative and sri management  years of experience part of new york life a fortune company  bn€ assets under management on march  convictiondriven investment solutions in  areas absolute return asset allocation equity fixed income sustainable  responsible investments presence in several european countries and in selected highpotential region amsterdam brussels dubai frankfurt geneva new york city london luxembourg madrid milan paris latest newsabout candriam  dec montreal carbon pledge – candriam discloses its carbon footprint  oct candriam embed principles of the uk stewardship code  sep candriam the right partner for sustainable development follow us on social media   contact candriam contact us candriam “conviction and responsibility in asset management” follow us on social media   contact candriam contact us  candriam all rights reserved  legal information  regulatory information  contact us × my country of residence austria belgium canada chili denmark finland france germany hong kong ireland italy japan luxembourg netherlands norway portugal rest of the world singapore slovakia south korea spain sweden switzerland united kingdom united states of america i confirm i am a nonqualified investor regulated  unregulated qualified investor professional investor private investor and agree with and will comply to the terms and conditions below by clicking on i agree you acknowledge having your usual residence in the country you will select if not then you acknowledge and accept that you must click on the button i disagree in order to return to the home page of this site where you can then make the right choice in fact the information available on this site is only intended for physical persons with their usual residence in the country concerned or for companies with their registered office in the country selected candriam therefore has no liability whatsoever for any harm of loss of opportunity resulting from the fact that you were given access to this site after selecting a country other than your own the information given on this site constitutes neither an offer nor an invitation to negotiate purchase andor sell the financial instruments mentioned by clicking on the i agree button below you acknowledge and accept that the use of and access to the information andor services accessible via this site is subject to acceptance of the provisions referred to in the legal information which on the example of this important information constitute the conditions imposed by candriam for the use of its site candriam reserves the right unilaterally and at any time to amend this important information as well as the legal information your use of the site is subject to the most recent version both of the important information and the legal information by clicking on i agree you acknowledge having your usual residence in the country you will select if not then you acknowledge and accept that you must click on the button i disagree in order to return to the home page of this site where you can then make the right choice in fact the information available on this site is only intended for physical persons with their usual residence in the country concerned or for companies with their registered office in the country selected candriam therefore has no liability whatsoever for any harm of loss of opportunity resulting from the fact that you were given access to this site after selecting a country other than your own the information given on this site constitutes neither an offer nor an invitation to negotiate purchase andor sell the financial instruments mentioned by clicking on the i agree button below you acknowledge and accept that the use of and access to the information andor services accessible via this site is subject to acceptance of the provisions referred to in the legal information which on the example of this important information constitute the conditions imposed by candriam for the use of its site candriam reserves the right unilaterally and at any time to amend this important information as well as the legal information your use of the site is subject to the most recent version both of the important information and the legal information decline confirm  agree × username password forgot your password  decline confirm  agree or become a member × disconnect manage account publications  candriambe by continuing to browse this site you are agreeing to cookies being used to offer content and services adapted to your interests find out more about cookies on candriamcom accept and continue on this site belgium austria canada chili denmark finland france germany hong kong ireland italy japan luxembourg netherlands norway portugal rest of the world singapore slovakia south korea spain sweden switzerland united kingdom united states of america english deutsch francais nederlands private investor i am a professional investor login candriamabout usmarket insightsfunds  solutionspress roomwork at candriam my subscriptions my wishlist contact search for a fund my subscriptions contact topics absolute returnasset allocationsrifixed incomemacroequities highlighted monthly strategic insightfrench electionsbrexitukall qasopinionsvideoresearch papers authors jan boudewijnsanton brenderisabelle cabienadège dufossénicolas forestphilippe noyardfabien orèvegeoffroy goenenflorence pisanikoen popleukoen van de maelerudi van den eyndewim van hyftepatrick zeenni resources publicationssri publicationsall qasresearch papersvideo article  belgium austria canada chili denmark finland france germany hong kong ireland italy japan luxembourg netherlands norway portugal rest of the world singapore slovakia south korea spain sweden switzerland united kingdom united states of america english deutsch francais nederlands private investor i am a professional investor login my subscriptions contact about usmarket insightsfunds  solutionspress roomwork at candriam search for a fund topics absolute returnasset allocationsrifixed incomemacroequities highlighted monthly strategic insightfrench electionsbrexitukall qasopinionsvideoresearch papers authors jan boudewijnsanton brenderisabelle cabienadège dufossénicolas forestphilippe noyardfabien orèvegeoffroy goenenflorence pisanikoen popleukoen van de maelerudi van den eyndewim van hyftepatrick zeenni resources publicationssri publicationsall qasresearch papersvideo article  candriam publications publications  resources publications find here candriams latest publications  corporate brochure magazine commercial brochures corporate brochures fact card snapshot of candriam investors group general information on candriam with keyfigures updated every quarter nl fr en   es it de activity report conviction delivers results as a toptier asset manager in europe we rely on strong values investment expertise honed over more than  years and since  a new solid shareholder new york life and a structure poised to generate new synergies nl fr en corporate brochure a trusted team a proven approach with eur bn assets under management candriam is a european multispecialist asset manager with a longterm track record nl fr en   es it de   magazine perspectives perspectives  the global macro forecast acceleration growth and increasing political uncertainties asset allocation outlook towards a possible end of the lowgrowth lowinflation environment inflation the revival of linkers thematic global equity time to embrace robots diversification what if it stops working emerging market investing in emerging market debt in     fr en   commercial brochures absolute performance take your portfolios to new heights with a trusted leader   nl fr en   es it de insurers solutions expertise that meets your exigencies candriam is one of europe’s most highly regarded asset managers as a multispecialist with a strong local presence in a number of countries and more than  years’ experience candriam has built its reputation on its ability to innovate and generate performance in partnership with its clients fr en mifid protection for every investor the markets in financial instruments directive mifid adopted on  april  is a european regulation governing the provision of investment services such as portfolio management and investment advice below you will find a detailed explanation of the principal measures outlined in the mifid directive and their impact on your professional relationship with candriam nl fr en pensions funds solution expertise within earshot candriam a pension fund partner you can trust nl fr en es it de sri brochure sustainable and responsible investments  years of expertise at your service nl fr en   es it de sripublications see more discover all qas see more research papers see more contact us we value your input and welcome your questions and comments contact candriam “conviction and responsibility in asset management” one of europe’s leading asset managers  experienced professionals multispecialist in traditional alternative and sri management  years of experience part of new york life a fortune company  bn€ assets under management on march  convictiondriven investment solutions in  areas absolute return asset allocation equity fixed income sustainable  responsible investments presence in several european countries and in selected highpotential region amsterdam brussels dubai frankfurt geneva new york city london luxembourg madrid milan paris latest newsabout candriam  dec montreal carbon pledge – candriam discloses its carbon footprint  oct candriam embed principles of the uk stewardship code  sep candriam the right partner for sustainable development follow us on social media   contact candriam contact us candriam “conviction and responsibility in asset management” follow us on social media   contact candriam contact us  candriam all rights reserved  legal information  regulatory information  contact us × my country of residence austria belgium canada chili denmark finland france germany hong kong ireland italy japan luxembourg netherlands norway portugal rest of the world singapore slovakia south korea spain sweden switzerland united kingdom united states of america i confirm i am a nonqualified investor regulated  unregulated qualified investor professional investor private investor and agree with and will comply to the terms and conditions below by clicking on i agree you acknowledge having your usual residence in the country you will select if not then you acknowledge and accept that you must click on the button i disagree in order to return to the home page of this site where you can then make the right choice in fact the information available on this site is only intended for physical persons with their usual residence in the country concerned or for companies with their registered office in the country selected candriam therefore has no liability whatsoever for any harm of loss of opportunity resulting from the fact that you were given access to this site after selecting a country other than your own the information given on this site constitutes neither an offer nor an invitation to negotiate purchase andor sell the financial instruments mentioned by clicking on the i agree button below you acknowledge and accept that the use of and access to the information andor services accessible via this site is subject to acceptance of the provisions referred to in the legal information which on the example of this important information constitute the conditions imposed by candriam for the use of its site candriam reserves the right unilaterally and at any time to amend this important information as well as the legal information your use of the site is subject to the most recent version both of the important information and the legal information by clicking on i agree you acknowledge having your usual residence in the country you will select if not then you acknowledge and accept that you must click on the button i disagree in order to return to the home page of this site where you can then make the right choice in fact the information available on this site is only intended for physical persons with their usual residence in the country concerned or for companies with their registered office in the country selected candriam therefore has no liability whatsoever for any harm of loss of opportunity resulting from the fact that you were given access to this site after selecting a country other than your own the information given on this site constitutes neither an offer nor an invitation to negotiate purchase andor sell the financial instruments mentioned by clicking on the i agree button below you acknowledge and accept that the use of and access to the information andor services accessible via this site is subject to acceptance of the provisions referred to in the legal information which on the example of this important information constitute the conditions imposed by candriam for the use of its site candriam reserves the right unilaterally and at any time to amend this important information as well as the legal information your use of the site is subject to the most recent version both of the important information and the legal information decline confirm  agree × username password forgot your password  decline confirm  agree or become a member × disconnect manage account ﻿ ls investment advisors llc increases stake in abbott laboratories nyseabt  markets daily daily ratings  news for abbott laboratories complete the form below to receive the latest headlines and analysts recommendationsfor abbott laboratories with our free daily email newsletter follow themarketsdaily the markets daily recent posts international speedway corporation isca shares sold by oppenheimerfunds inc ls investment advisors llc increases stake in abbott laboratories nyseabt national general holdings corp nasdaqnghc shares bought by principal financial group inc principal financial group inc sells  shares of nuance communications inc nuan northern oil  gas inc nog shares bought by principal financial group inc alliancebernstein lp buys  shares of installed building products inc nyseibp alliancebernstein lp has  stake in remax holdings inc rmax alliancebernstein lp sells  shares of green plains inc nasdaqgpre oppenheimerfunds inc acquires  shares of first commonwealth financial corporation nysefcf oppenheimerfunds inc purchases shares of  eqt corporation eqt platform specialty products corporation nysepah shares bought by alliancebernstein lp nottingham advisors inc has  stake in m company mmm mufg americas holdings corp has  million position in m company nysemmm amgen inc amgn position lowered by handelsbanken fonder ab pineno levin  ford asset management inc has  stake in m company nysemmm zacks investment research upgrades meritor inc mtor to buy lakeland bancorp inc lbai stock rating upgraded by zacks investment research american international group inc has  position in hortonworks inc nasdaqhdp hci group inc hci stake cut by american international group inc intrawest resorts holdings inc snow shares bought by american international group inc ls investment advisors llc increases stake in abbott laboratories nyseabt posted by kim johansen on jul th   no comments ls investment advisors llc boosted its position in abbott laboratories nyseabt by  during the first quarter according to its most recent f filing with the securities and exchange commission the firm owned  shares of the healthcare product maker’s stock after buying an additional  shares during the period ls investment advisors llc’s holdings in abbott laboratories were worth  at the end of the most recent quarter a number of other hedge funds have also recently added to or reduced their stakes in the company bank of new york mellon corp increased its stake in abbott laboratories by  in the first quarter bank of new york mellon corp now owns  shares of the healthcare product maker’s stock worth  after buying an additional  shares during the last quarter macquarie group ltd increased its stake in abbott laboratories by  in the fourth quarter macquarie group ltd now owns  shares of the healthcare product maker’s stock worth  after buying an additional  shares during the last quarter norges bank purchased a new stake in abbott laboratories during the fourth quarter worth about  boston partners increased its stake in abbott laboratories by  in the first quarter boston partners now owns  shares of the healthcare product maker’s stock worth  after buying an additional  shares during the last quarter finally ubs asset management americas inc increased its stake in abbott laboratories by  in the fourth quarter ubs asset management americas inc now owns  shares of the healthcare product maker’s stock worth  after buying an additional  shares during the last quarter  of the stock is currently owned by institutional investors and hedge funds get abbott laboratories alerts abbott laboratories nyseabt opened at  on thursday the stock has a market cap of  billion a pe ratio of  and a beta of  abbott laboratories has a month low of  and a month high of  the company’s day moving average price is  and its day moving average price is  abbott laboratories nyseabt last posted its earnings results on thursday july th the healthcare product maker reported  earnings per share eps for the quarter topping the consensus estimate of  by  the company had revenue of  billion during the quarter compared to analysts’ expectations of  billion abbott laboratories had a return on equity of  and a net margin of  the firm’s quarterly revenue was up  compared to the same quarter last year during the same quarter last year the firm earned  earnings per share on average equities analysts expect that abbott laboratories will post  eps for the current fiscal year the firm also recently announced a quarterly dividend which will be paid on tuesday august th shareholders of record on friday july th will be paid a dividend of  per share the exdividend date is wednesday july th this represents a  annualized dividend and a yield of  abbott laboratories’s dividend payout ratio dpr is  copyright violation warning this story was originally posted by markets daily and is owned by of markets daily if you are viewing this story on another domain it was stolen and republished in violation of us and international trademark and copyright law the original version of this story can be accessed at httpswwwthemarketsdailycomlsinvestmentadvisorsllcincreasesstakeinabbottlaboratoriesnyseabthtml abt has been the topic of a number of research reports cowen and company reaffirmed an “outperform” rating and issued a  price objective on shares of abbott laboratories in a research note on saturday april nd jefferies group llc reaffirmed a “buy” rating and issued a  price objective on shares of abbott laboratories in a research note on thursday june th thestreet raised abbott laboratories from a “c” rating to a “b” rating in a research note on monday july rd zacks investment research downgraded abbott laboratories from a “buy” rating to a “hold” rating in a research note on wednesday may st finally stifel nicolaus lifted their price objective on abbott laboratories from  to  and gave the stock a “buy” rating in a research note on wednesday may st four research analysts have rated the stock with a hold rating twelve have issued a buy rating and one has assigned a strong buy rating to the stock the stock has a consensus rating of “buy” and a consensus target price of  in other news insider jared watkin sold  shares of the firm’s stock in a transaction on thursday june th the stock was sold at an average price of  for a total transaction of  following the completion of the transaction the insider now directly owns  shares in the company valued at  the transaction was disclosed in a document filed with the sec which is available at this link also insider stephen r fussell sold  shares of the firm’s stock in a transaction on thursday june th the stock was sold at an average price of  for a total value of  following the transaction the insider now owns  shares of the company’s stock valued at  the disclosure for this sale can be found here  of the stock is owned by company insiders about abbott laboratories abbott laboratories is engaged in the discovery development manufacture and sale of a range of healthcare products the company operates through four segments established pharmaceutical products diagnostic products nutritional products and vascular products its established pharmaceutical products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the united states receive news  ratings for abbott laboratories daily  enter your email address below to receive a concise daily summary of the latest news and analysts ratings for abbott laboratories and related companies with marketbeatcoms free daily email newsletter latest news leave a reply click here to cancel reply name required mail will not be published required website funds search  candriamcom by continuing to browse this site you are agreeing to cookies being used to offer content and services adapted to your interests find out more about cookies on candriamcom accept and continue on this site rest of the world austria belgium canada chili denmark finland france germany hong kong ireland italy japan luxembourg netherlands norway portugal singapore slovakia south korea spain sweden switzerland united kingdom united states of america en professional investor i am a private investor login candriamabout usmarket insightsfunds  solutionspress roomwork at candriam my subscriptions my wishlist contact search for a fund my subscriptions contact rest of the world austria belgium canada chili denmark finland france germany hong kong ireland italy japan luxembourg netherlands norway portugal singapore slovakia south korea spain sweden switzerland united kingdom united states of america en professional investor i am a private investor login my subscriptions contact about usmarket insightsfunds  solutionspress roomwork at candriam search for a fund product class equities money market multi asset sriesg bonds absolute return protectedguaranteed geographical investment areas europe emerging markets asia world north america fund currency eur gbp aud sek usd chf jpy regulatory framework ucits other reset discover our funds funds available with these criteria view mode see all share class hide all share class an error occured please try again later isin code performance aum nav  year  years  years currency amount currency amount   morningstar inc all rights reserved some of the information contained in this document is the property of morningstar andor its information providers it is given without any guarantee as to its accuracy exhaustiveness or topicality its reproduction or redistribution is strictly forbidden candriam “conviction and responsibility in asset management” one of europe’s leading asset managers  experienced professionals multispecialist in traditional alternative and sri management  years of experience part of new york life a fortune company  bn€ assets under management on march  convictiondriven investment solutions in  areas absolute return asset allocation equity fixed income sustainable  responsible investments presence in several european countries and in selected highpotential region amsterdam brussels dubai frankfurt geneva new york city london luxembourg madrid milan paris latest newsabout candriam  dec montreal carbon pledge – candriam discloses its carbon footprint  oct candriam embed principles of the uk stewardship code  sep candriam the right partner for sustainable development follow us on social media   contact candriam contact us candriam “conviction and responsibility in asset management” follow us on social media   contact candriam contact us  candriam all rights reserved  legal information  regulatory information  contact us × my country of residence austria belgium canada chili denmark finland france germany hong kong ireland italy japan luxembourg netherlands norway portugal rest of the world singapore slovakia south korea spain sweden switzerland united kingdom united states of america i confirm i am a nonqualified investor regulated  unregulated qualified investor professional investor private investor and agree with and will comply to the terms and conditions below by clicking on i agree you acknowledge having your usual residence in the country you will select if not then you acknowledge and accept that you must click on the button i disagree in order to return to the home page of this site where you can then make the right choice in fact the information available on this site is only intended for physical persons with their usual residence in the country concerned or for companies with their registered office in the country selected candriam therefore has no liability whatsoever for any harm of loss of opportunity resulting from the fact that you were given access to this site after selecting a country other than your own the information given on this site constitutes neither an offer nor an invitation to negotiate purchase andor sell the financial instruments mentioned by clicking on the i agree button below you acknowledge and accept that the use of and access to the information andor services accessible via this site is subject to acceptance of the provisions referred to in the legal information which on the example of this important information constitute the conditions imposed by candriam for the use of its site candriam reserves the right unilaterally and at any time to amend this important information as well as the legal information your use of the site is subject to the most recent version both of the important information and the legal information by clicking on i agree you acknowledge having your usual residence in the country you will select if not then you acknowledge and accept that you must click on the button i disagree in order to return to the home page of this site where you can then make the right choice in fact the information available on this site is only intended for physical persons with their usual residence in the country concerned or for companies with their registered office in the country selected candriam therefore has no liability whatsoever for any harm of loss of opportunity resulting from the fact that you were given access to this site after selecting a country other than your own the information given on this site constitutes neither an offer nor an invitation to negotiate purchase andor sell the financial instruments mentioned by clicking on the i agree button below you acknowledge and accept that the use of and access to the information andor services accessible via this site is subject to acceptance of the provisions referred to in the legal information which on the example of this important information constitute the conditions imposed by candriam for the use of its site candriam reserves the right unilaterally and at any time to amend this important information as well as the legal information your use of the site is subject to the most recent version both of the important information and the legal information decline confirm  agree × username password forgot your password  decline confirm  agree or become a member × disconnect manage account ﻿ critical analysis altria group nysemo  lorillard lo  chaffey breeze daily ratings  news for altria group complete the form below to receive the latest headlines and analysts recommendationsfor altria group with our free daily email newsletter follow chaffeybreeze recent posts quantitative systematic strategies llc has  million position in cigna corporation nyseci oppenheimer holdings weighs in on visa inc’s fy earnings nysev critical analysis altria group nysemo  lorillard lo woodward inc nasdaqwwd issues earnings results beats expectations by  eps franklin resources inc nyseben lifted to “buy” at zacks investment research citigroup inc reiterates “buy” rating for anthem inc nyseantm the michaels companies inc nasdaqmik stock rating upgraded by thestreet citizens financial group inc nysecfg downgraded by thestreet atmos energy corporation nyseato upgraded to buy at zacks investment research conagra foods’ cag overweight rating reaffirmed at j p morgan chase  co avnet inc nyseavt stock rating upgraded by bidaskclub bmo capital markets analysts give apache corporation apa a  price target national bank holdings corp nbhc given a  price target at stephens analysts set  target price for ensync inc nasdaqesnc j p morgan chase  co initiates coverage on alibaba group holding limited nysebaba baker hughes a ge co nysebhi stock rating lowered by guggenheim nordlb analysts give hochtief ag frahot a € price target berkshire hills bancorp inc bhlb upgraded at zacks investment research pnc financial services group inc has  million stake in bryn mawr bank corporation nasdaqbmtc biocryst pharmaceuticals inc nasdaqbcrx stake held by state board of administration of florida retirement system critical analysis altria group nysemo  lorillard lo posted by harper lund on jul th   no comments altria group nyse mo and lorillard nyselo are both consumer staples companies but which is the superior business we will contrast the two businesses based on the strength of their risk earnings analyst recommendations valuation profitabiliy dividends and institutional ownership valuation and earnings get altria group alerts this table compares altria group and lorillard’s topline revenue earnings per share eps and valuation gross revenue pricesales ratio ebitda earnings per share priceearnings ratio altria group  billion   billion   lorillard na na na na na altria group has higher revenue and earnings than lorillard dividends altria group pays an annual dividend of  per share and has a dividend yield of  lorillard does not pay a dividend altria group pays out  of its earnings in the form of a dividend altria group has increased its dividend for  consecutive years and lorillard has increased its dividend for  consecutive years analyst ratings this is a summary of current ratings for altria group and lorillard as provided by marketbeatcom sell ratings hold ratings buy ratings strong buy ratings rating score altria group      lorillard     na altria group currently has a consensus price target of  suggesting a potential downside of  given altria group’s higher possible upside equities research analysts clearly believe altria group is more favorable than lorillard insider and institutional ownership  of altria group shares are owned by institutional investors  of altria group shares are owned by insiders strong institutional ownership is an indication that large money managers endowments and hedge funds believe a company will outperform the market over the long term profitability this table compares altria group and lorillard’s net margins return on equity and return on assets net margins return on equity return on assets altria group    lorillard  na  summary altria group beats lorillard on  of the  factors compared between the two stocks altria group company profile altria group inc is a holding company the company’s segments include smokeable products smokeless products and wine the company’s subsidiaries include philip morris usa inc pm usa which is engaged in the manufacture and sale of cigarettes in the united states john middleton co middleton which is engaged in the manufacture and sale of machinemade cigars and pipe tobacco and ust llc ust which through its subsidiaries including us smokeless tobacco company llc usstc and ste michelle wine estates ltd ste michelle is engaged in the manufacture and sale of smokeless tobacco products and wine its other operating companies include nu mark llc nu mark a subsidiary that is engaged in the manufacture and sale of tobacco products and philip morris capital corporation pmcc a subsidiary that maintains a portfolio of finance assets other subsidiaries include altria group distribution company and altria client services llc lorillard company profile lorillard inc lorillard is a tobacco company the company is engaged in the manufacture and sale of cigarettes products the company operates through two segments cigarettes and electronic cigarettes the cigarettes segment consists of the operations of lorillard inc lorillard tobacco and related entities the electronic cigarettes segment consists of the operations of loec inc blu ecigs cygnet uk trading limited skycig and related entities the company’s newport brand includes both menthol and nonmenthol product offerings the company’s product line includesbrand families marketed under the name kent true maverick and old gold these five brands include  various product offerings which vary in price taste flavor length and packaging the company also sells electronic cigarettes directly to adult consumers over the internet it produces cigarettes for both the premium and discount segments of the domestic cigarette market receive news  ratings for altria group daily  enter your email address below to receive a concise daily summary of the latest news and analysts ratings for altria group and related companies with marketbeatcoms free daily email newsletter latest news leave a reply click here to cancel reply name required mail will not be published required website ﻿ candriam luxembourg sca has  million stake in pfizer inc pfe  bnb daily daily ratings  news for pfizer inc complete the form below to receive the latest headlines and analysts recommendationsfor pfizer inc with our free daily email newsletter follow bnbdailynews recent posts pinnacle bank buys new position in microsoft corporation msft bennicas  associates inc has  position in apple inc aapl rigel pharmaceuticals rigl receiving somewhat positive news coverage analysis shows nationwide fund advisors boosts position in city office reit inc cio candriam luxembourg sca has  million stake in pfizer inc pfe general electric company ge stake raised by commonwealth financial services llc exxon mobil corporation xom stake lowered by cape ann savings bank somewhat positive media coverage very likely to affect kinder morgan kmi share price novavax nvax getting somewhat positive media coverage report finds sientra sien earns daily news impact rating of  favorable press coverage somewhat likely to affect old dominion freight line odfl stock price facebook inc nasdaqfb given “outperform” rating at robert w baird bidaskclub lowers southwest gas corporation nyseswx to strong sell adidas ag ads pt set at € by macquarie salem investment counselors inc has  position in national oilwell varco inc nysenov somewhat favorable news coverage extremely likely to impact identiv inve stock price under armour’s ua underperform rating reaffirmed at raymond james financial inc veritiv corporation vrtv upgraded by zacks investment research to “hold” unitedhealth group incorporated unh given “buy” rating at cantor fitzgerald wageworks inc wage downgraded by zacks investment research to hold candriam luxembourg sca has  million stake in pfizer inc pfe posted by renee johnson on jul st   no comments candriam luxembourg sca cut its position in shares of pfizer inc nysepfe by  during the first quarter according to its most recent disclosure with the securities and exchange commission the fund owned  shares of the biopharmaceutical company’s stock after selling  shares during the period candriam luxembourg sca’s holdings in pfizer were worth  at the end of the most recent quarter a number of other hedge funds also recently modified their holdings of pfe orbimed advisors llc boosted its position in shares of pfizer by  in the fourth quarter orbimed advisors llc now owns  shares of the biopharmaceutical company’s stock worth  after buying an additional  shares in the last quarter paulson  co inc acquired a new position in shares of pfizer during the fourth quarter worth about  eg advisors lp boosted its position in shares of pfizer by  in the first quarter eg advisors lp now owns  shares of the biopharmaceutical company’s stock worth  after buying an additional  shares in the last quarter prentiss smith  co inc boosted its position in shares of pfizer by  in the first quarter prentiss smith  co inc now owns  shares of the biopharmaceutical company’s stock worth  after buying an additional  shares in the last quarter finally carroll financial associates inc boosted its stake in shares of pfizer by  in the first quarter carroll financial associates inc now owns  shares of the biopharmaceutical company’s stock worth  after buying an additional  shares during the period  of the stock is owned by hedge funds and other institutional investors shares of pfizer inc nyse pfe opened at  on friday the firm has a market capitalization of  billion a pe ratio of  and a beta of  pfizer inc has a month low of  and a month high of  the stock has a  day moving average of  and a day moving average of  pfizer also was the target of unusually large options trading on tuesday investors bought  put options on the company this is an increase of  compared to the typical daily volume of  put options get pfizer inc alerts pfizer nysepfe last announced its quarterly earnings results on tuesday may nd the biopharmaceutical company reported  eps for the quarter topping the zacks’ consensus estimate of  by  pfizer had a return on equity of  and a net margin of  the business had revenue of  billion for the quarter compared to analysts’ expectations of  billion during the same period in the previous year the firm earned  eps the business’s quarterly revenue was down  on a yearoveryear basis on average equities research analysts predict that pfizer inc will post  eps for the current fiscal year the company also recently declared a quarterly dividend which will be paid on friday september st investors of record on friday august th will be given a dividend of  per share the exdividend date is wednesday august nd this represents a  annualized dividend and a dividend yield of  pfizer’s dividend payout ratio is presently  illegal activity warning this article was first posted by bnb daily and is the sole property of of bnb daily if you are reading this article on another domain it was stolen and reposted in violation of us and international copyright  trademark law the legal version of this article can be read at httpswwwbaseballnewsblogcompfizerincpfestakecutbycandriamluxembourgscaupdatedhtml a number of equities research analysts recently issued reports on pfe shares sanford c bernstein reiterated a “buy” rating and set a  target price on shares of pfizer in a research report on friday march th barclays plc reissued a “buy” rating and set a  price objective on shares of pfizer in a report on wednesday may rd cowen and company set a  price objective on shares of pfizer and gave the stock a “buy” rating in a report on monday july th bmo capital markets reissued a “hold” rating and set a  price objective on shares of pfizer in a report on thursday april th finally valuengine lowered shares of pfizer from a “buy” rating to a “hold” rating in a report on friday june nd two investment analysts have rated the stock with a sell rating twelve have issued a hold rating and ten have issued a buy rating to the stock the company has an average rating of “hold” and an average target price of  about pfizer pfizer inc pfizer is a researchbased global biopharmaceutical company the company is engaged in the discovery development and manufacture of healthcare products its global portfolio includes medicines and vaccines as well as consumer healthcare products the company manages its commercial operations through two business segments pfizer innovative health ih and pfizer essential health eh receive news  ratings for pfizer inc daily  enter your email address below to receive a concise daily summary of the latest news and analysts ratings for pfizer inc and related companies with marketbeatcoms free daily email newsletter latest news leave a reply click here to cancel reply name required mail will not be published required website ﻿  eps expected for spark therapeutics inc once this quarter  chaffey breeze daily ratings  news for spark therapeutics inc complete the form below to receive the latest headlines and analysts recommendationsfor spark therapeutics inc with our free daily email newsletter follow chaffeybreeze recent posts heidelbergcement ag hei receives € average pt from brokerages analysts set timken steel corporation tmst price target at   eps expected for spark therapeutics inc once this quarter bmo capital markets  given average recommendation of “” by analysts investors buy target corporation tgt on weakness after insider selling zacks brokerages anticipate nisource inc ni will announce quarterly sales of  million snyder’slance inc lnce receives average rating of “buy” from brokerages lexington realty trust lxp given average recommendation of “hold” by analysts insider buying peeks social ltd peek insider buys  shares of stock tcf financial corporation nysetcf given average rating of “hold” by brokerages analysts set rush enterprises inc nasdaqrusha target price at  a schulman inc nasdaqshlm receives average rating of “hold” from brokerages zacks morgan advanced ma nasdaqmcruf given average recommendation of “buy” by brokerages perrigo company nyseprgo expected to post earnings of  per share analysts anticipate charter communications inc nasdaqchtr will post earnings of  per share q  eps estimates for edwards lifesciences corporation nyseew decreased by suntrust banks cocacola company the ko given a  price target at barclays plc analysts set expectations for express scripts holding company’s fy earnings esrx leerink swann comments on gilead sciences inc’s q  earnings gild fy eps estimates for thermo fisher scientific inc raised by jefferies group tmo  eps expected for spark therapeutics inc once this quarter posted by oliver carreras on jul th   no comments equities research analysts expect spark therapeutics inc nasdaqonce to report  earnings per share eps for the current quarter zacks reports five analysts have made estimates for spark therapeutics’ earnings the lowest eps estimate is  and the highest is  spark therapeutics posted earnings per share of  during the same quarter last year which would suggest a negative year over year growth rate of  the company is expected to issue its next earnings results on wednesday august th according to zacks analysts expect that spark therapeutics will report fullyear earnings of  per share for the current year with eps estimates ranging from  to  for the next year analysts forecast that the company will report earnings of  per share with eps estimates ranging from  to  zacks’ eps calculations are a mean average based on a survey of sellside research analysts that cover spark therapeutics get spark therapeutics inc alerts spark therapeutics nasdaqonce last posted its quarterly earnings data on tuesday may th the biotechnology company reported  eps for the quarter missing analysts’ consensus estimates of  by  the business had revenue of  million during the quarter compared to the consensus estimate of  million spark therapeutics had a negative return on equity of  and a negative net margin of  the company’s revenue for the quarter was down  on a yearoveryear basis during the same quarter in the previous year the firm posted  earnings per share once has been the subject of several recent analyst reports ubs ag initiated coverage on shares of spark therapeutics in a research note on wednesday march th they issued a “buy” rating and a  target price for the company jefferies group llc initiated coverage on shares of spark therapeutics in a research note on monday july th they issued a “buy” rating and a  target price for the company stifel nicolaus reiterated a “buy” rating and issued a  target price on shares of spark therapeutics in a research note on monday april th cantor fitzgerald set a  target price on shares of spark therapeutics and gave the company a “buy” rating in a research note on tuesday may th finally bidaskclub upgraded shares of spark therapeutics from a “sell” rating to a “hold” rating in a research note on thursday june nd one equities research analyst has rated the stock with a sell rating four have given a hold rating and ten have given a buy rating to the company the company currently has a consensus rating of “buy” and a consensus target price of  in other spark therapeutics news cfo stephen w webster sold  shares of the firm’s stock in a transaction that occurred on monday april th the shares were sold at an average price of  for a total transaction of  following the completion of the sale the chief financial officer now directly owns  shares in the company valued at  the sale was disclosed in a document filed with the securities  exchange commission which is available at this hyperlink also insider katherine a high sold  shares of the firm’s stock in a transaction that occurred on monday april th the stock was sold at an average price of  for a total transaction of  following the sale the insider now owns  shares of the company’s stock valued at  the disclosure for this sale can be found here insiders have sold  shares of company stock valued at  over the last  days company insiders own  of the company’s stock large investors have recently modified their holdings of the company fmr llc increased its stake in shares of spark therapeutics by  in the first quarter fmr llc now owns  shares of the biotechnology company’s stock valued at  after buying an additional  shares during the period teachers advisors llc increased its stake in shares of spark therapeutics by  in the fourth quarter teachers advisors llc now owns  shares of the biotechnology company’s stock valued at  after buying an additional  shares during the period ubs asset management americas inc increased its stake in shares of spark therapeutics by  in the fourth quarter ubs asset management americas inc now owns  shares of the biotechnology company’s stock valued at  after buying an additional  shares during the period russell investments group ltd bought a new stake in shares of spark therapeutics during the fourth quarter valued at about  finally tocqueville asset management lp increased its stake in shares of spark therapeutics by  in the first quarter tocqueville asset management lp now owns  shares of the biotechnology company’s stock valued at  after buying an additional  shares during the period hedge funds and other institutional investors own  of the company’s stock copyright violation warning this article was published by chaffey breeze and is the property of of chaffey breeze if you are accessing this article on another domain it was stolen and republished in violation of us and international trademark  copyright legislation the correct version of this article can be accessed at httpswwwchaffeybreezecomepsexpectedforsparktherapeuticsinconcethisquarterhtml spark therapeutics once traded up  during trading on monday hitting  the stock had a trading volume of  shares the stock has a  day moving average price of  and a  day moving average price of  spark therapeutics has a month low of  and a month high of  the company’s market capitalization is  billion about spark therapeutics spark therapeutics inc is a gene therapy company the company focuses on treating orphan diseases it has a pipeline of product candidates targeting multiple rare blinding conditions hematologic disorders and neurodegenerative diseases its pipeline includes a product candidate targeting choroideremia chm which is in a phase iii clinical trial and a product candidate for hemophilia a which is in a phase iii clinical trial get a free copy of the zacks research report on spark therapeutics once for more information about research offerings from zacks investment research visit zackscom receive news  ratings for spark therapeutics inc daily  enter your email address below to receive a concise daily summary of the latest news and analysts ratings for spark therapeutics inc and related companies with marketbeatcoms free daily email newsletter latest news leave a reply click here to cancel reply name required mail will not be published required website candriam luxembourg sca  investment advisor  strassen sdzcbdefuasqertqvtyaedwyttwyrrvxry financial advisors online brokers more  search investment advisors × menu see all investment advisors overviewfirm registrationassets and accountsclient typesactivities and feesemployeesdisclosurescontact candriam luxembourg sca overviewfirm registrationassets and accountsmoreclient typesactivities and feesemployeesdisclosurescontact candriam luxembourg sca overview firm registration assets and accounts client types activities and fees employees disclosures contact references see all investment advisors guide share candriam luxembourg sca strassen luxembourg total assets under managementb united states dollarstotal number of employeestotal number of accountsaverage account balance united states dollars claim this listing star rated advisors advertisement shareoverviewcandriam luxembourg sca is a registered investment advisory firm located in strassen luxembourg the firm manages  accounts totaling an estimated  usd in assets under management its operations include  employees and is categorized as providing investment advisory services to  clients firm data current as of may   advertisement sharefirm registrationregistration details firm crd primary business namecandriam luxembourg sca organization typeother regulatorsec looking for a specific type of investment advisor check out the investment advisors homepage where you can apply custom filters to search through our database of  registered investment advisors for example click the button below to view all advisors in  or set the filter for a specific citysee all investment advisors in your city   advertisement shareassets and accountscurrent assets  accountsassets under management aum is the primary metric used to compare one investment advisory firm to another with  usd in aum candriam luxembourg sca is categorized as a large investment firm with assets above the prestigious one billion mark click here to view a list of other similarsized firms with aum above one billiondiscretionary assets under management united states dollarsnondiscretionary assets under management united states dollarstotal assets under managementb united states dollarsdiscretionary accountsnondiscretionary accountstotal number of accountsvisit the investment advisors homepage to sort and filter firms based on assets under management historical assets  accounts historical data is made available by the united states securities and exchange commission sec and is posted monthly on the freedom of information act foia section of the secs website the following graphs illustrate the  months of historical data available for this firm total aumbreakdownmoretotal aum sec report datetotal assets under management aumidfirm crd may  b united states dollarsapril  b united states dollarsmarch  b united states dollarsfebruary  b united states dollarsjanuary  b united states dollarsdecember  b united states dollarsnovember  b united states dollarsoctober  b united states dollarsseptember  b united states dollarsaugust  b united states dollarsjuly  b united states dollarsjune  b united states dollarsmay  b united states dollarsapril  b united states dollarsfebruary  b united states dollars breakdown sec report datediscretionary aumnondiscretionary aumidfirm crd may  b united states dollarsb united states dollarsapril  b united states dollarsb united states dollarsmarch  b united states dollarsb united states dollarsfebruary  b united states dollarsb united states dollarsjanuary  b united states dollarsb united states dollarsdecember  b united states dollarsb united states dollarsnovember  b united states dollarsb united states dollarsoctober  b united states dollarsb united states dollarsseptember  b united states dollarsb united states dollarsaugust  b united states dollarsb united states dollarsjuly  b united states dollarsb united states dollarsjune  b united states dollarsb united states dollarsmay  b united states dollarsb united states dollarsapril  b united states dollarsb united states dollarsfebruary  b united states dollarsb united states dollars accountsbreakdownmoreaccounts sec report datetotal number of accountsidfirm crd may  april  march  february  january  december  november  october  september  august  july  june  may  april  february   breakdown sec report datediscretionary accountsnondiscretionary accountsidfirm crd may  april  march  february  january  december  november  october  september  august  july  june  may  april  february   credio is a finance site that uses graphiq’s semantic technology to deliver deep insights via datadriven articles visualizations and research tools deep insights from finance data knowledge delivered › shareclient typestypes of clients served banks or thriftspooled investment vehiclespension and profit sharing planscharitiescorporations or other businessesstate or municipal entitiesinsurance companiesfirm crd idia firm name percent percent percent percent percent percent percent assets attributed to each client type banks or thriftspooled investment vehiclespension and profit sharing planscharitiescorporations or other businessesstate or municipal entitiesinsurance companiescompany nameidia firm name percent percent percent percent percent percent percentcandriam luxembourg sca the sec form adv organizes client types into  categories candriam luxembourg sca reports working with  of these  client types the firm reports serving a total of  clients and does not have any financial planning clientsselect investment advisors by types of clients   advertisement shareactivities and feesareas of businessadvisory activities and servicesindividuals or small businessesportfolio management for businesses or institutional clientsselection of other advisorsperiodicals or newsletterssecurity portfolioseducational seminarsother advisory services nocompensationadvisory feespercentage of assetsperformancebased feesother fee types noclick here to select investment advisors based on types of fees charged  shareemployeesby categorytotal number of employeesinvestment adviser representativeslicensed insurance agentsbrokerdealer registered repsthe largest firm in our database has  employees other firms report having no employees at all on the investment advisors homepage you can sort and filter firms by number of employees or select other advanced criteriaselect investment advisors by number of employees   advertisement sharedisclosurespublic disclosure statements as reported on form advthe sec keeps track of disclosures for the  categories listed below candriam luxembourg sca has disclosures in  of these categories on the research topic home page you can view a presorted list of all investment advisory firms with zero disclosuresregulatory criminal false statements or omissions to sec or cftcnonefelony chargesnonesec or cftc violationsnonefelony convictionsnonebusiness suspensions restrictions or revocationsnonemisdemeanor chargesnonesec or cftc entered an order against advisornonemisdemeanor convictionsnonecivil money penalty or cease and desist ordersnone  false statements or omissions to other regulatornonecivil violations of regulations or statutesenjoinments with domestic or foreign courtsnonerestrictions or denials of businessnoneviolations of investmentrelated statutesnoneregulator entered orders against advisorcivil action dismissed by a settlement agreementnonedenials or suspensions of registrationnonesubject to any civil proceedingnonefalse statements or omissions to selfreg orgnone  violation of regulatory rulesnoneother associated with any business suspensionsnoneany professional authorization revokednonemembership suspensions or expulsionsnonesubject to any regulatory proceedingnone view a complete list of all investment advisory firms in our database sdzcbdefuasqertqvtyaedwyttwyrrvxry sharecontact infoprincipal office main office phone     main office fax      main office address  route darlonserenity bloc bstrassen lluxembourg website candriamcom still searching for the right advisor try the investment advisors homepage where you can sort and filter  registered investment advisors by fee type advisory services location and more you can click the button below to view all advisors in your city or set the filter for more advanced specific criteriasee all investment advisors in your city   × references source sec as of may   show details  hide details  was this page helpful yes no blkhol email welcome to hi we see you would like to submit a rating please login or create an account to do so thank you sign in with login with google login with facebook well never post without your permission dont have an account sign up now privacy terms  conditions   graphiq inc all rights reserved support terms privacy ad choices and cookie policy cryolife nysecry stock price news  analysis  marketbeat cryolife company profile nysecry company profile analyst ratings earnings history earnings estimates dividend history insider trade headlines social media chart about cryolife nysecry cryolife inc cryolife is a medical device manufacturer and processor and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures the company operates through two segments medical devices and preservation services the medical devices segment includes medical devices such as bioglue surgical adhesive biofoam surgical matrix onx life technologies holdings inc valves and surgical products cardiogenesis cardiac laser therapy product line perclot and photofix photofix is a pericardial patch stabilized using a dyemediated photofixation process that requires no glutaraldehyde the preservation services segment includes external services such as preservation of cardiac and vascular tissues the cardiac and vascular human tissues distributed by cryolife include the cryovalve sg pulmonary heart valve and the cryopatch sg pulmonary cardiac patch both of which are processed using cryolifes synergraft technology industry sector and symbol sector medical industry medical equipment supplies  distribution  nec subindustry health care equipment symbol nysecry cusip  web wwwcryolifecom capitalizationmarket cap  millionoutstanding shares average prices day moving avg  day moving avg  week range    petrailing pe ratio foreward pe ratio pe growth sales  book valueannual revenue  millionprice  sales book value  per shareprice  book  profitabilityebidta  millionnet margins return on equity return on assets debtdebttoequity ratio current ratio quick ratio miscaverage volume  shsbeta short ratio    frequently asked questions for cryolife nysecry what is cryolifes stock symbol cryolife trades on the new york stock exchange nyse under the ticker symbol cry how were cryolifes earnings last quarter cryolife inc nysecry posted its earnings results on monday july th the company reported  eps for the quarter topping the thomson reuters consensus estimate of  by  the business earned  million during the quarter compared to the consensus estimate of  million cryolife had a return on equity of  and a net margin of  cryolifes revenue was up  on a yearoveryear basis during the same quarter last year the company earned  eps view cryolifes earnings history what guidance has cryolife issued on next quarters earnings cryolife updated its fy earnings guidance on monday july th the company provided earnings per share eps guidance of  for the period compared to the thomson reuters consensus estimate of  the company issued revenue guidance of  million compared to the consensus revenue estimate of  million where is cryolifes stock going where will cryolifes stock price be in   equities research analysts have issued  year price targets for cryolifes stock their forecasts range from  to  on average they expect cryolifes share price to reach  in the next year view analyst ratings for cryolife who are some of cryolifes key competitors some companies that are related to cryolife include asante solutions pump km group holdings ktwo cardiovascular systems csii orasure technologies osur orthofix international nv ofix intersect ent xent atricure atrc meridian bioscience vivo consort medical plc csrt landauer ldr invacare corporation ivc antares pharma atrs exactech exac staar surgical company staa syneron medical elos sientra sien ocular therapeutix ocul and transenterix trxc who are cryolifes key executives cryolifes management team includes the folowing people james patrick mackin chairman of the board president chief executive officerd ashley lee cpa chief financial officer chief operating officer executive vice presidentjames m mcdermid chief human resource officerjohn davis senior vice president  global sales and marketingwilliam matthews senior vice president  operations quality and regulatoryamy d horton cpa chief accounting officerjean f holloway chief compliance officer vice president general counsel secretaryscott b capps vice president  clinical researchdavid c gale phd vice president  research  developmentjames bullock director who owns cryolife stock cryolifes stock is owned by a variety of of institutional and retail investors top institutional shareholders include thomson horstmann  bryant inc  great west life assurance co can  eqis capital management inc  aperio group llc  louisiana state employees retirement system  and capstone asset management co  company insiders that own cryolife stock include amy horton c elkins ronald david ashley lee james benson james p mackin ronald d mccall and scott b capps view institutional ownership trends for cryolife who sold cryolife stock who is selling cryolife stock cryolifes stock was sold by a variety of institutional investors in the last quarter including capstone asset management co company insiders that have sold cryolife stock in the last year include amy horton and scott b capps view insider buying and selling for cryolife who bought cryolife stock who is buying cryolife stock cryolifes stock was bought by a variety of institutional investors in the last quarter including thomson horstmann  bryant inc eqis capital management inc state of alaska department of revenue aperio group llc municipal employees retirement system of michigan creative planning and louisiana state employees retirement system view insider buying and selling for cryolife how do i buy cryolife stock shares of cryolife can be purchased through any online brokerage account popular online brokerages include vanguard brokerage services td ameritrade etrade scottrade fidelity and charles schwab what is cryolifes stock price today one share of cryolife stock can currently be purchased for approximately  marketbeat community rating for cryolife nyse crycommunity ranking   out of    outperform votes   vote outperformunderperform votes   vote underperformtotal votes  marketbeats community ratings are surveys of what our community members think about cryolife and other stocks vote outperform if you believe the stock will outperform the sp  over the long term vote underperform if you believe the stock will underperform the sp  over the long term you may vote once every thirty days analyst ratings consensus ratings for cryolife nysecry how are consensus ratings calculated marketbeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months since brokers often use different ratings systems each rating is normalized to a standardized rating score of  sell  hold  buy or  strong buy consensus ratings scores are calculated using the mean average of the number of normalized sell hold buy and strong buy ratings each stocks consensus rating is derived from its calculated consensus ratings score   sell   hold   buy   strong buy marketbeats consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve monthsmarketbeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and marketbeat has received a report that coverage was dropped ratings from certain research firms that issue ratings using purely quantitative methods such as zacks vetr and valuengine are not included in consensus calculations marketbeats consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available dataratings breakdown  buy ratingsconsensus ratingbuy score consensus price target   upside analysts ratings history for cryolife nysecry show only the most recent rating from each brokerage all ratings for this stock datefirmactionratingprice targetimpact on share pricedetailsnorthland securitiesreiterated ratingbuylowladenburg thalmann financial servicesupgradeneutral  buynacanaccord genuityreiterated ratingbuynapiper jaffray companiesreiterated ratingoverweightnalake street capitalinitiated coveragebuynadata available from  forward earnings earnings history for cryolife nysecryearnings history by quarter for cryolife nyse crydatequarterconsensus estimateactual epsrevenue estimateactual revenuerelease linkconference calldetailsq  million millionviewnaq  million millionviewnaq million millionviewlistenq million millionviewlistenq million millionviewlistenq million millionviewlistenq million millionviewlistenq million millionviewlistenq million millionviewlistenq million millionviewlistenq million millionviewlistenq million millionviewlistenq million millionviewlistenq million millionviewlistenq million millionviewlistenq million millionviewlistenq  million millionviewlistenq  million millionviewlistenq  million millionviewlistenq million millionviewnaviewnaviewnaviewnaviewnaviewnaviewnaviewnadata available from  forward estimates earnings estimates for cryolife nysecry eps consensus estimate quarternumber of estimateslow estimatehigh estimateaverage estimateq q q q q data provided by zacks investment research dividends current dividend information for cryolife nysecrymost recent dividenddividend yielddividend growth  year averagepayout ratio trailing  months of earnings  based on this years estimates based on next years estimatestrack record years of consecutive dividend growthdividend history by quarter for cryolife nyse cryannouncedperiodamountyieldexdividend daterecord datepayable datequarterlyquarterlyquarterlyquarterlyquarterlyquarterlyquarterlyquarterlyquarterlyquarterlyquarterlyquarterlydata available from  forward insider trades insider trading and institutional ownership history for cryolife nysecryinsider ownership percentage institutional ownership percentage insider trades by quarter for cryolife nysecrytransaction dateinsider nametitlebuysellnumber of sharesaverage share pricetotal transactiondetailsamy hortonvpsell  scott b cappsvpsell  c elkins ronalddirectorsell  ronald d mccalldirectorsell  james bensondirectorsell  c elkins ronalddirectorsell  c elkins ronalddirectorsell  james p mackinceobuy  scott b cappsvpsell  david ashley leecfosell  david ashley leecfosell  david ashley leecfosell  james bensondirectorsell  james bensondirectorsell  steven g andersonchairmansell  bruce g andersonvpsell  bruce g andersonvpsell  c elkins ronalddirectorsell  james bensondirectorsell  bruce g andersonvpsell  steven g andersonchairmansell  bruce g andersonvpsell  bruce g andersonvpsell  david ashley leecfosell  david ashley leecfosell  jeffrey w burrisvpsell  c elkins ronalddirectorsell  bruce g andersonvpsell  steven g andersonceosell  amy hortoncaosell  david fronkvpsell  steven andersonceosell  bruce andersonvpsell  jeffrey burrisvpsell  jeffrey burrisvpsell  steven andersonceosell  c elkins ronalddirectorsell  jeffrey w burrisvpsell  bruce andersonvpsell  amy hortoncaosell  ronald d mccalldirectorsell  ronald d mccalldirectorsell  c elkins ronalddirectorsell  data available from  forward headlines headline trends for cryolife nysecry latest headlines for cryolife nysecry source all sources trusted sources marketbeatcom bloomberg marketwatch motley fool nasdaq reuters seeking alpha the street the wall street journal yahoo finance dateheadlinecryolife inc cryus earnings analysis q  by the numbers  july  financeyahoocom  july  at  pmedited transcript of cry earnings conference call or presentation jul pm gmtfinanceyahoocom  july  at  pminvestor network cryolife inc to host earnings callfinanceyahoocom  july  at  pmcryolife posts q profitfinanceyahoocom  july  at  pmcryolife inc nysecry posts quarterly earnings results beats expectations by  epswwwamericanbankingnewscom  july  at  pmcryolife inc nysecry receives average recommendation of buy from analystswwwamericanbankingnewscom  july  at  pmcryolife inc cry updates fy earnings guidancewwwamericanbankingnewscom  july  at  pmcryolife reports second quarter  financial resultsfinanceyahoocom  july  at  pmstryker poised on solid product portfolio and acquisitionsfinanceyahoocom  july  at  pmcryolife inc nysecry scheduled to post earnings on mondaywwwamericanbankingnewscom  july  at  ammckesson mck poised on improving generic and brand marketwwwzackscom  july  at  pmfresenius medical fms well poised on growth strategy financeyahoocom  july  at  pmmasimo masi rainbow super dcimini sensor now ce markedfinanceyahoocom  july  at  pmamerisourcebergens pharmedium slows down competition rifewwwzackscom  july  at  pmheart valve devices market  cagr by  with tavr and tmvr says a research report available at reportsnreportswwwmarketwatchcom  july  at  pmamerisourcebergens pharmedium slows down competition rifefinanceyahoocom  july  at  pmcryolife announces release date and teleconference call details for  second quarter financial resultsfinanceyahoocom  july  at  pmamy horton sells  shares of cryolife inc cry stockwwwamericanbankingnewscom  june  at  amcryolife hits a week high whats driving the stockwwwnasdaqcom  june  at  pmvarian rides on oncology and proton therapy businessesfinanceyahoocom  june  at  pmcryolife hits a week high whats driving the stockfinanceyahoocom  june  at  pmquintiles q oce software to simplify commercial functionsfinanceyahoocom  june  at  pmetfs with exposure to cryolife inc  june  financeyahoocom  june  at  pmluminex lmnx banks on portfolio strength view impressivefinanceyahoocom  june  at  amcryolife inc cry upgraded to buy at zacks investment researchwwwamericanbankingnewscom  june  at  pmcryolife inc cry forecasted to earn q  earnings of  per sharewwwamericanbankingnewscom  june  at  ametfs with exposure to cryolife inc  june  financeyahoocom  june  at  pmfirst analysis weighs in on cryolife incs q  earnings crywwwamericanbankingnewscom  june  at  amprosthetic heart valveartificial heart valve market worth  billion usd by wwwmarketwatchcom  june  at  pmcryolife inc cry receives consensus rating of buy from brokerageswwwamericanbankingnewscom  may  at  pmetfs with exposure to cryolife inc  may  financeyahoocom  may  at  pmc r bard inc bcrfinanceyahoocom  may  at  pmetfs with exposure to cryolife inc  may  financeyahoocom  may  at  pmcryolife cry receives daily news impact rating of wwwamericanbankingnewscom  may  at  pmcryolife inc cry given average recommendation of buy by brokerageswwwamericanbankingnewscom  may  at  amcryolife inc cryus earnings analysis q  by the numbers  may  financeyahoocom  may  at  pmcryolife cry receives news sentiment score of wwwamericanbankingnewscom  april  at  pmcryolife inc – value analysis nysecry  april  financeyahoocom  april  at  pmcryolife inc cry earns buy rating from northland securitieswwwamericanbankingnewscom  april  at  pmcryolife inc breached its  day moving average in a bullish manner  cryus  april  financeyahoocom  april  at  amedited transcript of cry earnings conference call or presentation apr pm gmtfinanceyahoocom  april  at  amcryolife to present at deutsche bank nd annual health care conferencefinanceyahoocom  april  at  pmcryolife q profit downwwwrttnewscom  april  at  pmbriefcryolife reports q nongaap earnings per share wwwreuterscom  april  at  pmcryolife announces onx aortic heart valve proact study results to be presented at american association for thoracic surgery centennial meetingwwwbizjournalscom  april  at  pmetfs with exposure to cryolife inc  april  financeyahoocom  april  at  pmwhy cryolife inc jumped higherwwwfoolcom  april  at  pmcryolife reports first quarter  financial resultsfinanceyahoocom  april  at  amcryolife posts q profitfinanceyahoocom  april  at  amcryolife inc cry posts earnings results beats estimates by  epswwwamericanbankingnewscom  april  at  am social chart cryolife cry chart for thursday july   this page was last updated on  by marketbeatcom staff